Oncology & Cancer
Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research ...
Jul 7, 2011
0
0